Introducing OLAR® - A novel Oral Long Acting Release Platform

3/16/2021 12:15 - 12:50

  • Continuous drug delivery to the upper GI tract
  • Orally administered, non-invasive
  • To be used for drugs in which traditional ER formulation strategies cannot support the required pharmacokinetic profile
  • Versatile platform, suitable for multiple APIs and enabling high drug loading

Elijahu Berkovich, Head of Emerging Science and Innovation, Clexio Biosciences